Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis
暂无分享,去创建一个
Xiaoding Xu | Rong Li | Q. Shen | Junyue Fang | S.J. Tan | Rong Liu | Shiyu Tan
[1] Chenjie Xu,et al. Design principles of microneedles for drug delivery and sampling applications , 2022, Materials Today.
[2] Yuanjin Zhao,et al. Biologics‐Loaded Photothermally Dissolvable Hyaluronic Acid Microneedle Patch for Psoriasis Treatment , 2022, Advanced Functional Materials.
[3] Teng Shen,et al. Tacrolimus nanocrystals microneedle patch for plaque psoriasis. , 2022, International journal of pharmaceutics.
[4] Huacheng He,et al. Latest on biomaterial-based therapies for topical treatment of psoriasis. , 2022, Journal of materials chemistry. B.
[5] B. Cheng,et al. A Modified Hyaluronic Acid–Based Dissolving Microneedle Loaded With Daphnetin Improved the Treatment of Psoriasis , 2022, Frontiers in Bioengineering and Biotechnology.
[6] Ruijie Chen,et al. Alantolactone-loaded chitosan/hyaluronic acid nanoparticles suppress psoriasis by deactivating STAT3 pathway and restricting immune cell recruitment , 2022, Asian journal of pharmaceutical sciences.
[7] Haiyan Jia,et al. Par3 regulates the asymmetric division of basal stem cells in psoriasis via the Par3/mInsc/LGN signaling axis. , 2022, Cellular immunology.
[8] E. Papadavid,et al. Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential , 2022, International journal of molecular sciences.
[9] C. H. J. Choi,et al. Alkyl-Terminated Gold Nanoparticles as a Self-Therapeutic Treatment for Psoriasis. , 2021, Nano letters.
[10] V. Sobolev,et al. Analysis of PPARγ Signaling Activity in Psoriasis , 2021, International journal of molecular sciences.
[11] T. Torres,et al. Bimekizumab: the new drug in the biologics armamentarium for psoriasis , 2021, Drugs in context.
[12] E. Sánchez-López,et al. Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics , 2021, International journal of molecular sciences.
[13] Yu Wang,et al. Emerging Functional Biomaterials as Medical Patches. , 2021, ACS nano.
[14] Y. Ping,et al. Microneedle-assisted genome editing: A transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders , 2021, Science Advances.
[15] T. Gambichler,et al. Increased expression profile of NCSTN, Notch and PI3K/AKT3 in hidradenitis suppurativa , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[16] K. Schäkel,et al. The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis. , 2020, The Journal of clinical investigation.
[17] Ming-zhu Yin,et al. miR-205-5p inhibits psoriasis-associated proliferation and angiogenesis: Wnt/β-catenin and mitogen-activated protein kinase signaling pathway are involved. , 2020, The Journal of dermatology.
[18] M. Obeidat,et al. IL-33/13 Axis and IL-4/31 Axis Play Distinct Roles in Inflammatory Process and Itch in Psoriasis and Atopic Dermatitis , 2020, Clinical, cosmetic and investigational dermatology.
[19] Wei Zhao,et al. Cimifugin ameliorates imiquimod-induced psoriasis by inhibiting oxidative stress and inflammation via NF-κB/MAPK pathway , 2020, Bioscience reports.
[20] Kaiming Zhang,et al. Different epigenome regulation and transcriptome expression of CD4+ and CD8+ T cells from monozygotic twins discordant for psoriasis , 2020, The Australasian journal of dermatology.
[21] P. Bolfa,et al. Modulatory effects of Cornus sanguinea L. mediated green synthesized silver nanoparticles on oxidative stress, COX-2/NOS2 and NFkB/pNFkB expressions in experimental inflammation in Wistar rats. , 2020, Materials science & engineering. C, Materials for biological applications.
[22] C. Gabay,et al. IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis , 2020, Life Science Alliance.
[23] L. Dobrucki,et al. Pathogenesis of psoriasis in the “omic” era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances , 2020, Postepy dermatologii i alergologii.
[24] A. Grossman,et al. Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases , 2021, Arthritis care & research.
[25] C. Akdis,et al. Nanoparticle-coupled topical methotrexate can normalize immune responses and induce tissue remodeling in psoriasis. , 2020, The Journal of investigative dermatology.
[26] Upendra Bulbake,et al. Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis , 2019, Journal of liposome research.
[27] Q. Lu,et al. Topical administration of nanocarrier miRNA‐210 antisense ameliorates imiquimod‐induced psoriasis‐like dermatitis in mice , 2019, The Journal of dermatology.
[28] Jinjin Zhu,et al. Hyaluronic Acid Dissolving Microneedle Patch Loaded with Methotrexate for Improved Treatment of Psoriasis. , 2019, ACS applied materials & interfaces.
[29] Guanglin Zhang,et al. FGF-7 facilitates the process of psoriasis by inducing TNF-α expression in HaCaT cells. , 2019, Acta biochimica et biophysica Sinica.
[30] Yingyuan Yu,et al. IL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients , 2019, Front. Immunol..
[31] Xiaoyun Yu,et al. FGF19 sustains the high proliferative ability of keratinocytes in psoriasis through the regulation of Wnt/GSK‐3β/β‐catenin signalling via FGFR4 , 2019, Clinical and experimental pharmacology & physiology.
[32] T. Beikler,et al. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases , 2019, International journal of molecular sciences.
[33] D. Kalvakolanu,et al. IL-33 contributes to disease severity in Psoriasis-like models of mouse. , 2019, Cytokine.
[34] Özgür Gündüz. JAK/STAT pathway modulation: Does it work in dermatology? , 2019, Dermatologic therapy.
[35] Adriana Rendon,et al. Psoriasis Pathogenesis and Treatment , 2019, International journal of molecular sciences.
[36] R. Weichselbaum,et al. A Critical Role of the IL-1β-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis. , 2019, The Journal of investigative dermatology.
[37] E. Halilovic,et al. Serum Concentrations of Interferon Gamma (IFN-γ) in Patients with Psoriasis: Correlation with Clinical Type and Severity of the Disease , 2018, Medical archives.
[38] C. Buerger. Epidermal mTORC1 Signaling Contributes to the Pathogenesis of Psoriasis and Could Serve as a Therapeutic Target , 2018, Front. Immunol..
[39] J. Krueger,et al. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis , 2018, The Journal of Immunology.
[40] Liangdan Sun,et al. NFKB1 mediates Th1/Th17 activation in the pathogenesis of psoriasis. , 2018, Cellular immunology.
[41] Qing Sun,et al. miR-320b Is Down-Regulated in Psoriasis and Modulates Keratinocyte Proliferation by Targeting AKT3 , 2018, Inflammation.
[42] M. Crisan,et al. Topical silver and gold nanoparticles complexed with Cornus mas suppress inflammation in human psoriasis plaques by inhibiting NF‐κB activity , 2018, Experimental dermatology.
[43] Tingting Zheng,et al. MAPK Phosphatase-1 Deficiency Exacerbates the Severity of Imiquimod-Induced Psoriasiform Skin Disease , 2018, Front. Immunol..
[44] L. Tsoi,et al. RNA-Seq Analysis of IL-1B and IL-36 Responses in Epidermal Keratinocytes Identifies a Shared MyD88-Dependent Gene Signature , 2018, Front. Immunol..
[45] K. Ross,et al. Towards topical microRNA‐directed therapy for epidermal disorders , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[46] P. Wolf,et al. Blocking mTOR Signalling with Rapamycin Ameliorates Imiquimod-induced Psoriasis in Mice. , 2017, Acta dermato-venereologica.
[47] Jan Kremláček,et al. Roles of miR-31 and endothelin-1 in psoriasis vulgaris: pathophysiological functions and potential biomarkers. , 2017, Physiological research.
[48] J. Krueger,et al. Psoriasis pathogenesis and the development of novel targeted immune therapies , 2017, The Journal of allergy and clinical immunology.
[49] N. Balato,et al. Mechanistic target of rapamycin complex 1 is involved in psoriasis and regulated by anti‐TNF‐α treatment , 2017, Experimental dermatology.
[50] B. King,et al. JAK inhibitors in dermatology: The promise of a new drug class , 2017, Journal of the American Academy of Dermatology.
[51] Hao Yin,et al. Delivery technologies for genome editing , 2017, Nature Reviews Drug Discovery.
[52] D. Schwartz,et al. JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects , 2017, Drugs.
[53] S. Arias-Santiago,et al. Increased expression of microRNA‐155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[54] S. John,et al. A systematic review of worldwide epidemiology of psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[55] Mandip Singh,et al. Novel amphiphilic lipid augments the co‐delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[56] Lisa A. DeLouise,et al. Nanoparticle-Enabled Transdermal Drug Delivery Systems for Enhanced Dose Control and Tissue Targeting , 2016, Molecules.
[57] A. Reza,et al. Effectiveness of Topical Corticosteroid, Topical Calcineurin Inhibitors and Combination of Them in the Treatment of Vitiligo. , 2016, Mymensingh medical journal : MMJ.
[58] S. Suresh,et al. A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation , 2015, Pharmaceutical development and technology.
[59] T. Torres,et al. Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors , 2016, European Journal of Dermatology.
[60] Hong Wang,et al. NF-κB-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis , 2015, Nature Communications.
[61] F. Ahmad,et al. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy , 2015, Expert opinion on drug delivery.
[62] Massimo Gadina,et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.
[63] Y. Kalia,et al. Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[64] Mandip Singh,et al. Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. , 2014, Nanomedicine.
[65] M. Crisan,et al. Green synthesis, characterization and anti-inflammatory activity of silver nanoparticles using European black elderberry fruits extract. , 2014, Colloids and surfaces. B, Biointerfaces.
[66] Lone Skov,et al. MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. , 2014, Journal of dermatological science.
[67] S. Chimenti,et al. IL-6 as a Druggable Target in Psoriasis: Focus on Pustular Variants , 2014, Journal of immunology research.
[68] Mayte Suárez-Fariñas,et al. Immunology of psoriasis. , 2014, Annual review of immunology.
[69] D. Bogdanos,et al. The Role of p38 MAPK in the Aetiopathogenesis of Psoriasis and Psoriatic Arthritis , 2013, Clinical & developmental immunology.
[70] M. Mahmoudi,et al. Expression patterns of Th1/Th2 transcription factors in patients with guttate psoriasis. , 2013, Acta microbiologica et immunologica Hungarica.
[71] Luigi Calzolai,et al. Gold nanoparticles downregulate interleukin-1β-induced pro-inflammatory responses. , 2013, Small.
[72] Y. Sakaguchi,et al. Serum Cytokines Correlated with The Disease Severity of Generalized Pustular Psoriasis , 2013, Disease markers.
[73] A. Pivarcsi,et al. MicroRNA-31 Is Overexpressed in Psoriasis and Modulates Inflammatory Cytokine and Chemokine Production in Keratinocytes via Targeting Serine/Threonine Kinase 40 , 2013, The Journal of Immunology.
[74] M. Suárez-Fariñas,et al. A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin , 2011, The Journal of investigative dermatology.
[75] M. Suárez-Fariñas,et al. Human keratinocytes' response to injury upregulates CCL20 and other genes linking innate and adaptive immunity , 2011, The Journal of investigative dermatology.
[76] Weixiong Zhang,et al. Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. , 2011, Human molecular genetics.
[77] L. Jensen. Targeting the IL-1 family members in skin inflammation. , 2010, Current opinion in investigational drugs.
[78] J. Zhang,et al. Decreased colony formation of high proliferative potential colony‐forming cells and granulocyte‐macrophage colony‐forming units and increased Hes‐1 expression in bone marrow mononuclear cells from patients with psoriasis , 2010, The British journal of dermatology.
[79] James T. Elder,et al. Evidence for altered Wnt signaling in psoriatic skin. , 2010, The Journal of investigative dermatology.
[80] M. Wittmann,et al. Interleukin‐1 from epithelial cells fosters T cell‐dependent skin inflammation , 2010, The British journal of dermatology.
[81] W. Leonard,et al. Atopic Dermatitis-Like Disease and Associated Lethal Myeloproliferative Disorder Arise from Loss of Notch Signaling in the Murine Skin , 2010, PloS one.
[82] J. Saurat,et al. High Prevalence of Potential Drug-Drug Interactions for Psoriasis Patients Prescribed Methotrexate or Cyclosporine for Psoriasis: Associated Clinical and Economic Outcomes in Real-World Practice , 2010, Dermatology.
[83] A. Ishida-Yamamoto,et al. Serum cytokines and growth factor levels in Japanese patients with psoriasis , 2009, Clinical and experimental dermatology.
[84] M. Jakobsen,et al. Amelioration of Psoriasis by Anti-TNF-α RNAi in the Xenograft Transplantation Model. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[85] I. Faraoni,et al. miR-155 gene: a typical multifunctional microRNA. , 2009, Biochimica et biophysica acta.
[86] Chi-Hsien Liu,et al. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[87] A. Rebora. Conventional therapies for psoriasis. , 2011, Reumatismo.
[88] H. Dinh,et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation , 2007, The Journal of experimental medicine.
[89] P. Janson,et al. MicroRNAs: Novel Regulators Involved in the Pathogenesis of Psoriasis? , 2007, PloS one.
[90] O. Arican,et al. Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity , 2005, Mediators of inflammation.
[91] F. Nestle,et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.
[92] V. Ambros. The functions of animal microRNAs , 2004, Nature.
[93] D. Bartel,et al. MicroRNA-Directed Cleavage of HOXB8 mRNA , 2004, Science.
[94] K. Gordon,et al. The immunology of psoriasis and biologic immunotherapy. , 2003, Journal of the American Academy of Dermatology.
[95] Mark Lebwohl,et al. Psoriasis , 1906, The Lancet.
[96] W. Jochum,et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. , 1994, The Journal of investigative dermatology.